Information de reference pour ce titreAccession Number: | 00000013-200010000-00003.
|
Author: | Sommerschild, H. T. 1; Kirkeboen, K. A. 1,2
|
Institution: | (1)Institute for Experimental Medical Research, Ulleval Hospital, Oslo, and (2)Department of Anaesthesia, Ulleval Hospital, Oslo, Norway
|
Title: | Adenosine and cardioprotection during ischaemia and reperfusion - an overview.[Article]
|
Source: | Acta Anaesthesiologica Scandinavica. 44(9):1038-1055, October 2000.
|
Abstract: | Adenosine is a local hormone, with numerous tissue-specific biological functions. In the myocardium, adenosine is released in small amounts at constant basal rate during normoxia. During ischaemia the production of adenosine increases several fold due to breakdown of adenosine triphosphate (ATP). Increased production of adenosine causes coronary vasodilatation. Thus, adenosine couples myocardial metabolism and flow during ischaemia and is called a homeostatic or "retaliatory metabolite". Furthermore, adenosine has electrophysiological effects in supraventricular tissue, causing a decrease in heart rate. In 1985 it was discovered that adenosine also exerts cardioprotective effects directly on cardiomyocytes. The aim of this review is to give an overview of the role of adenosine as a directly cytoprotective agent during myocardial ischaemia and reperfusion. We will focus on its effects on the myocytes, elicited by stimulation of adenosine receptors in sarcolemma, which triggers intracellular signalling systems. We will also address the new aspect that adenosine can influence regulation of gene expression. There is evidence that the myocardium is capable of endogenous adaptation in response to ischaemia, namely "hibernation" and early and late phases of "preconditioning". Endogenous substances produced during ischaemia probably trigger these responses. We will discuss the role of adenosine in these different settings. Adenosine can be given exogenously through intravasal routes; however, this review will also focus on the effects of endogenously produced adenosine. We will discuss pharmacological ways to increase endogenous levels of adenosine, and the effects of such interventions during ischaemia and reperfusion. Finally, we will review results from studies in humans together with relevant experimental studies, and indicate potential therapeutic implications of adenosine.
(C) 2000 The Acta Anaesthesiologica Foundation.
|
Author Keywords: | Adenosine; cardioprotection; ischemia; myocardium; nucleosides; reperfusion.
|
References: | 1. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologishe Gewebelehre. Berlin: Hirschwald, 1858: 122.
2. Jennings RB, Murry CE, Steenbergen Jr C, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990: 82 (Suppl II): II2-II12.
3. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia [Review]. Annu Rev Med 1991: 42: 225-246.
4. Janssen M, van der Meer P, de Jong JW. Antioxidant defences in rat, pig, guinea pig, and human hearts: comparison with xanthine oxidoreductase activity. Cardiovasc Res 1993: 27: 2052-2057.
5. Bristow JD, Arai AE, Anselone CG, Pantely GA. Response to myocardial ischaemia as a regulated process [Point of View]. Circulation 1991: 84: 2580-2587.
6. Opie LH. The multifarious spectrum of ischemic left ventricular dysfunction: relevance of new ischemic syndromes [Review]. J Mol Cell Cardiol 1996: 28: 2403-2414.
7. Ross J Jr. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation [Point of View]. Circulation 1991: 83: 1076-1083.
8. Heusch G, Schulz R. Hibernating myocardium: A review. J Mol Cell Cardiol 1996: 28: 2359-2372.
9. Heusch G, Ferrari R, Hearse D, Ruigrok TJC, Schulz R. "Myocardial hibernation" - questions and controversies [Review]. Cardiovasc Res 1997: 36: 301-309.
10. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975: 56: 978-985.
11. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986: 74: 1124-1136.
12. de Jong JW, de Jonge R, Marchesani A, Janssen M, Bardamante S. Controversies in preconditioning [Review]. Cardiovasc Drugs Ther 1996: 10: 767-773.
13. Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G, Sumeray MS. Ischaemic preconditioning: present position and future directions [Review]. Cardiovasc Res 1998: 37: 21-33.
14. Wegelin I, Pane G, Finelli C, Clo C, Zanfanti ML. Age-related changes of AMP breakdown in chicken heart. Comp Biochem Physiol 1995: 110A: 27-31.
15. Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol (Lond) 1929: 68: 213-237.
16. Berne RM. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am J Physiol 1963: 204: 317-322.
17. Hori M, Kitakaze M. Adenosine, the heart and coronary circulation [Review]. Hypertension 1991: 18: 565-574.
18. Mullane K, Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine [Review]. J Mol Cell Cardiol 1995: 27: 1041-1054.
19. Mubagwa K, Mullane K, Flameng W. Role of adenosine in the heart and circulation [Review]. Cardiovasc Res 1996: 32: 797-813.
20. Shrader J, Deussen A, Decking UKM. Adenosine metabolism and transport in the mammalian heart. In: Pelleg A, Belardinelli L, eds. Effects of extracellular adenosine and ATP on cardiomyocytes. Texas: RG Landes Company, 1998: 39-75.
21. Van Wylen DGL, Schmit TJ, Lasley RD, Gingell RL, Mentzer Jr RM. Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia. Am J Physiol 1992: 262: H1934-H1938.
22. Martin BJ, Lasley RD, Mentzer Jr RM. Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. Am J Physiol 1997: 272: H1857-H1865.
23. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989: 256: C799-C806.
24. Delyani JA, Van Wylen DGL. Endocardial and epicardial interstitial purines and lactate during graded ischemia. Am J Physiol 1994: 266: H1019-H1026.
25. Wikstrom G, Ronquist G, Nilsson S, Maripu E, Waldenstrom A. Continuous monitoring of energy metabolites using microdialysis during myocardial ischemia in the pig. Eur Heart J 1995: 16: 339-347.
26. Kirkeboen KA, Aksnes G, Lande K, Ilebekk A. Role of adenosine for reactive hyperemia in normal and stunned porcine myocardium. Am J Physiol 1992: 263: H1119-H1127.
27. Schrader J. Adenosine. A homeostatic metabolite in cardiac enegrgy metabolism [Editorial]. Circulation 1990: 81: 389-391.
28. Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980: 47: 807-813.
29. Belardinelli L, Shryock JC, Song Y, Wang D, Srinivas M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes [Review]. FASEB J 1995: 9: 359-365.
30. Freeman GL, Colston JT, Hultman J. Influence of adenosine on left ventricular performance in conscious dogs. Am J Physiol 1990: 258: H424-H430.
31. Ely SW, Mentzer RM, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985: 90: 549-556.
32. Ely SW, Berne R. Protective effects of adenosine in myocardial ischemia [Review]. Circulation 1992: 85: 893-904.
33. Gauthier NS, Headrick JP, Matherne GP. Myocardial function in the working mouse heart overexpressing cardiac A1 adenosine receptors. J Mol Cell Cardiol 1998: 30: 187-193.
34. Sekili S, Jeroudi O, Tang X-L, Zughaib M, Sun J-Z, Bolli R. Effect of adenosine on myocardial "stunning" in the dog. Circ Res 1995: 76: 82-94.
35. Fralix TA, Murphy E, London RE, Steenbergen C. Protective effects of adenosine in the perfused rat heart: changes in metabolism and intracellular ion homeostasis. Am J Physiol 1993: 264: C986-C994.
36. Finegan BA, Lopaschuk GD, Coulson CS, Clanahan AS. Adenosine alters glucose use during ischemia and reperfusion in isolated rat hearts. Circulation 1993: 87: 900-908.
37. Janier MF, Vanoverschelde J-LJ, Bergmann SR. Adenosine protects ischemic and reperfused myocardium by receptor-mediated mechanisms. Am J Physiol 1993: 264: H163-H170.
38. Lasley RD, Mentzer Jr RM. Adenosine increases lactate release and delays onset of contracture during global low-flow ischaemia. Cardiovasc Res 1993: 27: 96-101.
39. Vander Heide R, Reimer K. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996: 31: 711-718.
40. Van Belle H. Nucleoside transport inhibition for cardioprotection: new perspectives for the clinic [Review]. Drug Develop Res 1993: 28: 344-348.
41. Bunch FT, Thornton J, Cohen MV, Downey JM. Adenosine is an endogenous protectant against stunning during repetitive ischemic episodes in the heart. Am Heart J 1992: 124: 1440-1445.
42. Rynning SE, Brunvand H, Birkeland S, Hexeberg E, Grong K. Endogenous adenosine attenuates myocardial stunning by antiadrenergic effects exerted during ischemia and not during reperfusion. J Cardiovasc Pharmacol 1995: 25: 432-439.
43. Liu G, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994: 28: 1057-1061.
44. Zhao ZQ, McGee S, Nakanishi K, Toombs CF, Johnston WE, Ashar MS et al. Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit. Circulation 1993: 88: 709-719.
45. Zhao ZQ, Nakanishi K, McGee S, Tan P, Vinten-Johansen J. A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischemia. Cardiovasc Res 1994: 28: 270-279.
46. Headrick J, Willis RJ. Mediation by adenosine of bradycardia in rat heart during graded global ischemia. Pflugers Arch 1989: 412: 618-623.
47. Angello DA, Headrick JP, Coddington NM, Berne RM. Adenosine antagonism decreases metabolic but not functional recovery from ischaemia. Am J Physiol 1991: 260: H193-H200.
48. Offstad J, Kirkeboen KA, Ilebekk A, Downing SE. ATP gated potassium channels in acute myocardial hibernation and reperfusion. Cardiovasc Res 1994: 28: 872-880.
49. Gao Z-P, Downey HF, Fan W-L, Mallet RT. Does interstitial adenosine mediate acute hibernation of guinea pig myocardium? Cardiovasc Res 1995: 29: 796-804.
50. Schulz R, Rose J, Post H, Heusch G. Regional short-term myocardial hibernation in swine does not involve endogenous adenosine or KATP channels. Am J Physiol 1995: 268: H2294-H2301.
51. Galinanes M, Qiu Y, Van Belle H, Hearse DJ. Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischaemic and blood reperfused myocardium. Cardiovasc Res 1993: 27: 90-95.
52. Zughaib ME, Abd-Elfattah AS, Jeroudi MO, Sun J-Z, Sekili S, Tang X-L et al. Augmentation of endogenous adenosine attenuates myocardial "stunning" independently of coronary flow or hemodynamic effects. Circulation 1993: 88: 2359-2369.
53. Abd-Elfattah AS, Jessen ME, Wechsler AS. Nucleoside trapping during reperfusion prevents ventricular dysfunction, "stunning", in absence of adenosine. J Thorac Cardiovasc Surg 1994: 108: 269-278.
54. Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 1994: 24: 846-852.
55. Dorheim TA, Hoffman A, Van Wylen DGL, Mentzer Jr RM. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery 1991: 110: 136-145.
56. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury [Short review]. Cardiovasc Res 1993: 27: 43-47.
57. Kollias-Baker C, Ruble J, Dennis D, Bruns RF, Linden J, Belardinelli L. Allosteric enhancer PD81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ Res 1994: 75: 961-971.
58. Blumenthal DS, Hutchins GM, Jugdutt BI, Becker LC. Salvage of ischemic myocardium by dipyridamole in the conscious dog. Circulation 1981: 64: 915-923.
59. Sommerschild HT, Grund F, Offstad J, Jynge P, Ilebekk A, Kirkeboen KA. Importance of endogenous adenosine during ischemia and reperfusion in neonatal porcine hearts. Circulation 1997: 96: 3094-3103.
60. Li Y, Kloner RA. The cardioprotective effects of ischemic "preconditioning" are not mediated by adenosine receptors in rat hearts. Circulation 1993: 87: 1642-1648.
61. Van Belle H, Wynants J, Goossens F. Formation and release of nucleosides in the ischemic myocardium. Is the guineapig an exception? Basic Res Cardiol 1985: 80: 653-660.
62. Skladanowski AC, Smolenski RT, Tavenir M, de Jong JW, Yacoub MH, Seymour A-ML. Soluble forms of 5'-nucleotidase in rat and human heart. Am J Physiol 1996: 270: H1493-H1500.
63. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine [Review]? Cardiovasc Res 1993: 27: 68-76.
64. Olah ME, Stiles GL. Adenosine receptor-mediated signal transduction. In: Pelleg A, Belardinelli L, eds. Effects of extracellular adenosine and ATP on cardiomyocytes. Texas: RG Landes Company, 1998: 7-31.
65. Bolling SF, Olszanski DA, Bove EL, Childs KF. Enhanced myocardial protection during global ischemia with 5'-nucleotidase inhibitors. J Thorac Cardiovasc Surg 1992: 103: 73-77.
66. Pridjian AK, Bove EL, Bolling SF, Childs KF, Brosamer KS, Lupinetti FM. Developmental differences in myocardial protection in response to 5'-nucleotidase inhibition. J Thorac Cardiovasc Surg 1994: 107: 520-526.
67. Headrick JP, Ely SW, Matherne GP, Berne RM. Myocardial adenosine, flow, and metabolism during adenosine antagonism and adrenergic stimulation. Am J Physiol 1993: 264: H61-H70.
68. Haessler R, Kuzume K, Chien GL, Wolff RA, Davis RF, Van Winkle DM. Anaesthetics alter the magnitude of infarct limitation by ischemic preconditioning. Cardiovasc Res 1994: 28: 1574-1580.
69. Cohen MV, Snell KS, Tsuchida A, Van Wylen DG, Downey JM. Effects of anesthesia and K+ ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Basic Res Cardiol 1995: 90: 410-417.
70. Buljubasic N, Stowe DF, Marijic J, Roerig DL, Kampine JP, Bosnjak ZJ. Halothane reduces release of adenosine, inosine, and lactate with ischemia and reperfusion in isolated hearts. Anesth Analg 1993: 76: 54-62.
71. Homeister JW, Hoff PT, Fletcher DD, Lucchesi BR. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 1990: 82: 595-608.
72. Schjott J, Brurok H, Jynge P. Lidocaine interactions with exogenous and endogenous adenosine in the isolated rat heart. Pharmacol Toxicol 1994: 75: 212-217.
73. Guth BD, Schulz R, Heusch G. Time course and mechanisms of contractile dysfunction during acute myocardial ischemia [Review]. Circulation 1993: 87 (Suppl IV): IV35-IV42.
74. Figueredo VM, Brandes R, Weiner MW, Massie BM, Camacho SA. Cardiac contractile dysfunction during mild coronary flow reductions is due to an altered calcium-pressure relationship in rat hearts. J Clin Invest 1992: 90: 1794-1802.
75. Camacho SA, Figueredo VM, Brandes R, Weiner MW. Ca2+-dependent fluorescence transients and phosphate metabolism during low-flow ischemia in rat hearts. Am J Physiol 1993: 265: H114-H122.
76. Kihara Y, Grossman W, Morgan JP. Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. Circ Res 1989: 65: 1029-1044.
77. Koretzune Y, Marban E. Relative roles of Ca2+-dependent and Ca2+-independent mechanisms in hypoxic contractile dysfunction. Circulation 1990: 82: 528-535.
78. Koretzune Y, Coretti MC, Kusuoka H, Marban E. Mechanism of early ischemic contractile failure. Inexcitability, metabolite accumulation, or vascular collapse? Circ Res 1991: 68: 255-262.
79. Decking UKM, Reffelmann T, Schrader J, Kammermeier H. Hypoxia-induced activation of KATP channels limits energy depletion in the guinea pig heart. Am J Physiol 1995: 269: H734-H742.
80. Krause S, Hess ML. Characterization of cardiac sarcoplasmic reticulum dysfunction during short-term, normothermic global ischemia. Circ Res 1984: 55: 176-184.
81. Kitakaze M, Marban E. Cellular mechanism of the modulation of contractile function by coronary perfusion pressure in ferret hearts. J Physiol (Lond) 1989: 414: 455-472.
82. Marban E. Excitation-contraction coupling in hibernating myocardium [Review]. Basic Res Cardiol 1995: 90: 19-22.
83. Valdivia CR, Lasley RD, Hegge JO, Valdivia HH, Mentzer RM. Adenosine pretreatment prevents myocardial stunning-induced reduction of ryanodine receptor function. Circulation 1996: 94 (Suppl): A185.
84. Xu K, Zweier JL, Becker LC. Hydroxyl radical inhibits sarcoplasmic reticulum Ca2+-ATPase function by direct attack on the ATP binding site. Circ Res 1997: 80: 76-81.
85. Neumann J, Gupta RC, Jones LR, Bodor GS, Bartel S, Krause E-G et al. Interaction of [beta]-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. J Mol Cell Cardiol 1995: 27: 1655-1667.
86. Sato H, Hori M, Kitakaze M, Takashima S, Inoue M, Kitabatake A et al. Endogenous adenosine blunts [beta]-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium. Circulation 1992: 85: 1594-1603.
87. Diamond GA, Forrester JS, De Luz PL, Wyatt HL, Swan H. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978: 95: 204-209.
88. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985: 72 (Suppl V): V123-V135.
89. Rahimtoola SH. The hibernating myocardium [Editorial]. Am Heart J 1989: 177: 211-221.
90. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: Evidence for the "hibernating myocardium" [Editorial]. J Am Coll Cardiol 1986: 8: 1467-1470.
91. Node K, Kitakaze M, Kosaka H, Komamura K, Minamino T, Inoue M et al. Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation 1996: 93: 356-364.
92. Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993: 88: 684-695.
93. Fang HK, Sturgeon C, Segil LJ, Ripper RL, Law WR. Cardiac contractile function during coronary stenosis in dogs: association of adenosine in glycolytic dependence. Am J Physiol 1997: 272: H2195-H2203.
94. Sommerschild HT, Lunde PK, Deindl E, Jynge P, Ilebekk A, Kirkeboen KA. Elevated levels of endogenous adenosine alter metabolism and enhance reduction in contractile function during low-flow ischemia. Associated changes in expression of Ca2+-ATPase and phospholamban. J Mol Cell Cardiol 1999: 31: 1897-1911.
95. Bolukoglu H, Liedtke AJ, Nellis SH, Eggelston AM, Subramanian R, Renstrom B. An animal-model of chronic coronary stenosis resulting in hibernating myocardium. Am J Physiol 1992: 263: H20-H29.
96. Shen Y-T, Vatner SF. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs. Hibernation versus stunning? Circ Res 1995: 76: 479-488.
97. Chen C, Chen L, Fallon JT, Ma L, Li L, Bow L et al. Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion. A pig model of myocardial hibernation. Circulation 1996: 94: 507-516.
98. Elsasser A, Schlepper M, Klovekorn W-P, Cai W-j, Zimmermann R, Muller K-D et al. Hibernating myocardium. An incomplete adaptation to ischemia. Circulation 1997: 96: 2920-2931.
99. Vanoverschelde JLJ, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M et al. Mechanisms of chronic regional ostischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993: 87: 1513-1523.
100. Gerber BL, Vanoverschelde J-LJ, Bol A, Michel C, Labar D, Wijns W et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996: 94: 651-659.
101. Meininger CJ, Granger HJ. Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial cells. Am J Physiol 1990: 258: H198-H206.
102. Ethier MF, Chander V, Dobson Jr JG. Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol 1993: 265: H131-H138.
103. Fischer S, Sharma HS, Karliczek GF, Schaper W. Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Mol Brain Res 1995: 28: 141-148.
104. Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, Kira Y. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Comm 1994: 204: 318-324.
105. Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension 1996: 27: 786-793.
106. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts. Role of A2B receptors. Circulation 1997: 96: 2656-2666.
107. Picano E, Michelassi C. Chronic dipyridamole as a "novel" antianginal drug: the collateral hypothesis. Cardiovasc Res 1997: 33: 666-670.
108. Lorbar M, Skalova K, Nabi A, Chung ES, Meyer TE. Activation of the adenosine A1 receptor attenuates the release of norepinephrine from the presynaptic sympathetic neurons in hypertrophied myocardium. Circulation 1999: 100 (Suppl): I730.
109. Wagner DR, Combes A, McTierman C, Sanders VJ, Lemster B, Feldman AM. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-[alpha]. Circ Res 1998: 82: 47-56.
110. Chung ES, Perlini S, Aurigemma GP, Fenton RA, Dobson JG Jr, Meyer TE. Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. J Hypertens 1998: 16: 1813-1822.
111. Downey JM, Cohen MV. Signal transduction in ischemic preconditioning [Review]. Adv Exp Med Biol 1997: 430: 39-55.
112. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993: 72: 1293-1299.
113. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning [Review]. Cardiovasc Res 1993: 27: 3-8.
114. Downey JM, Cohen MV, Ytrehus K, Liu Y. Cellular mechanisms in ischemic preconditioning: the role of adenosine and protein kinase C [Review]. Ann NY Acad Sci 1994: 723: 82-98.
115. Crestanello JA, Lingle DM, Kamelgard J, Millili J, Whitman GJ. Ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminiscence study. J Surg Res 1996: 65: 53-58.
116. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Okazaki Y et al. [alpha]1-adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation 1995: 91: 2226-2234.
117. Wikstrom BG, Ronquist G, Waldenstrom A. Dynamics of myocardial metabolism in the preconditioned porcine heart studied using continuous microdialysis. Eur Heart J 1995: 16: 563-569.
118. Lasley RD, Mentzer Jr RM. Preconditioning and its potential role in myocardial protection during cardiac surgery [Review]. J Card Surg 1995: 10: 349-353.
119. Dekker LRC. Toward the heart of ischemic preconditioning [Editorial]. Cardiovasc Res 1998: 37: 14-20.
120. Baxter GF, Pharms MR, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 1994: 90: 2993-3000.
121. Baxter GF, Yellon DM. Time course of delayed myocardial protection after transient adenosine A1-receptor activation in the rabbit. J Cardiovasc Pharmacol 1997: 29: 631-638.
122. Baxter GF, Zaman MJS, Kerac M, Yellon DM. Protection against global ischemia in the rabbit isolated heart 24 hours after transient adenosine A1 receptor activation [Letter]. Cardiovasc Drugs Ther 1997: 11: 83-85.
123. Dana A, Yamashita N, Baxter GF, Yellon DM. Involvement of protein kinases and manganese-superoxide dismutase in adenosine induced delayed preconditioning (Abstracts). J Mol Cell Cardiol 1998: 30: A75.
124. Heads RJ, Punn A, Yellon DM. Cytoprotection of neonatal rat cardiomyocytes 24 hours following simulated ischemia is both adenosine A1-receptor and PKC-dependent. J Mol Cell Cardiol 1996: 28: A47.
125. Qiu Y, Tang X-L, Park S-W, Sun J-Z, Kalya A, Bolli R. The early and late phases of ischemic preconditioning. A comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. Circ Res 1997: 80: 730-742.
126. Muller CA, Baxter GF, Latouf SE, McCarthy J, Opie LH, Yellon DM. Delayed protection against infarction in pig heart after PTCA balloon inflations. J Mol Cell Cardiol 1998: 30: A74.
127. Maldonado C, Qiu Y, Tang X-L, Cohen MV, Auchampach J, Bolli R. Role of adenosine receptors in late preconditioning against myocardial stunning in conscious rabbit. Am J Physiol 1997: 273: H1324-H1332.
128. Takano H, Bolli R, Tang X-L, Yang Z, Black R, Auchampach JA. Activation of A1 or A3 receptors produces delayed protection against infarction in conscious rabbits by a mechanism involving KATP channels. Circulation 1999: 100 (Suppl): A56.
129. Carroll R, Yellon DM. Mechanisms of delayed preconditioning in a human cardiac cell line. Circulation 1999: 100 (Suppl): A631.
130. Zhao T, Hines DS, Krottapalli K, Emani VR, Xi L, Kukreja RC. Adenosine induced delayed pharmacological preconditioning involves p38 MAP kinase signalling in mouse heart. Circulation 1999: 100 (Suppl): A563.
131. Baxter GF, Yellon DM. ATP-sensitive K+ channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation. J Mol Cell Cardiol 1999: 31: 981-989.
132. Dana A, Skarli M, Yellon DM. Delayed adenosine A1 receptor induced preconditioning: role of the 27 kDa heat shock protein (hsp27). Circulation 1999: 100 (Suppl): A57.
133. Dana A, Jonassen AK, Yellon DM. Transient adenosine A1 receptor activation induces delayed cardioprotection in rats: role of Mn-superoxide-dismutase. Circulation 1999: 100 (Suppl): A57.
134. Zhao T, Xi L, Chelliah JC, Levasseur JE, Kukreja RC. Nitric oxide mediates adenosine A1 receptor induced delayed protection: evidence from pharmacological inhibition and gene knockout mice. Circulation 1999: 100 (Suppl): A242.
135. Bell RM, Rees DD, Yellon DM. The protection observed during delayed preconditioning of the heart appears independently of iNOS: a study in iNOS knockout mice. Circulation 1999: 100 (Suppl): A242.
136. Dana A, Baxter GF, Yellon DM. Adenosine A1 receptor induced preconditioning: role of nitric oxide synthase. Circulation 1999: 100 (Suppl): A631.
137. Tsuchida A, Thompson R, Olsson RA, Downey JM. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart. J Mol Cell Cardiol 1994: 26: 303-311.
138. Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998: 31: 1142-1149.
139. Alkhulaifi AM, Jenkins DP, Pugsley WB, Treasure T. Ischaemic preconditioning and cardiac surgery [Review]. Eur J Cardiothorac Surg 1996: 10: 792-798.
140. Tsuchida A, Liu GS, Mullane K, Downey JM. Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovasc Res 1993: 27: 116-120.
141. Tsuchida A, Yang X-M, Burckhartt B, Mullane KM, Cohen MV, Downey JM. Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits. Cardiovasc Res 1995: 29: 653-657.
142. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992: 86: 979-985.
143. Mentzer Jr RM, Bunger R, Lasley RD. Adenosine enhanced preservation of myocardial function and energetics. Possible involvement of the adenosine A1 receptor system [Review]. Card Res 1993: 27: 28-35.
144. Kuan C-J, Wells JN, Jackson EK. Endogenous adenosine restrains renin release in conscious rats. Circ Res 1990: 66: 637-646.
145. Velasco CE, Jackson EK, Morrow JA, Vitola JV, Inagami T, Forman MB. Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischemia and reperfusion. Cardiovasc Res 1993: 27: 121-128.
146. Felsch A, Stocker K, Borchard U. Adenosine A1 and A2 receptor agonists alter cardiac functions and prostacyclin release in the isolated guinea-pig heart. Eur J Pharmacol 1994: 263: 261-268.
147. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995: 92: 2135-2141.
148. Kirsch GE, Codina J, Birnbaumer L, Brown AM. Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990: 259: H820-H826.
149. Iliodromitis EK, Miki T, Liu G-S, Downey JM, Cohen MV, Kremastinos DT. The PKC activator PMA preconditions rabbit heart in the presence of adenosine receptor blockade: is 5'-nucleotidase important? J Mol Cell Cardiol 1998: 30: 2201-2211.
150. Narayan P, Valdivia HH, Mentzer Jr RM, Lasley RD. Adenosine A1 receptor stimulation antagonizes the negative inotropic effects of PKC activator dioctanoylglycerol. J Mol Cell Cardiol 1998: 30: 913-921.
151. Cronstein BN, Daguma L, Nichols D, Hutchinson AJ, Williams M. The adenosine/neutrophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 1990: 85: 1150-1157.
152. Hannon JP, Pfannkuche HJ, Fozard JR. A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. Br J Pharmacol 1995: 115: 945-952.
153. Shneyvays V, Nawrath H, Jacobson KA, Shainberg A. Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 1998: 243: 383-397.
154. Ikeda U, Kurosaki K, Ohya K-I, Shimada K. Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res 1997: 35: 168-174.
155. Heads RJ, Latchman DS, Yellon DM. Differential stress protein mRNA expression during early ischaemic preconditioning in the rabbit heart and its relationship to adenosine receptor function. J Mol Cell Cardiol 1995: 27: 2133-2148.
156. Mubagwa K. Sarcoplasmic reticulum function during myocardial ischaemia and reperfusion [Review]. Cardiovasc Res 1995: 30: 166-175.
157. Frass O, Sharma HS, Knoll R, Duncker DJ, McFalls EO, Verdouw PD et al. Enhanced gene expression of calcium regulatory proteins in stunned porcine myocardium. Cardiovasc Res 1993: 27: 2037-2043.
158. Knoll R, Arras M, Zimmermann R, Schaper J, Schaper W. Changes in gene expression following short coronary occlusions studied in porcine hearts with run-on assays. Cardiovasc Res 1994: 28: 1062-1069.
159. Assayg P, Charlemagne D, Marty I, de Leiris J, Lompre AM, Boucher F et al. Effects of sustained low-flow ischemia on myocardial function and calcium-regulating proteins in adult and senescent rat hearts. Cardiovasc Res 1998: 38: 169-180.
160. Abraham S, Young RF, Canty Jr JM. Post-ischaemic dysfunction following short-term hibernation is not associated with increased mRNA for sarcoplasmic reticulum calcium regulatory proteins. Circulation 1996: 94 (Suppl): A186.
161. Luss H, Bokni P, Heusch G, Muller FU, Neumann J, Schmitz W et al. Expression of calcium regulatory proteins in short-term hibernation and stunning in the in situ porcine heart. Cardiovasc Res 1998: 37: 606-617.
162. Deindl E, Neubauer E, Elsasser A, Zimmermann R, Schaper W. Reduced contractile function characteristic for hibernating human heart is not mediated by phospholamban. Ann N Y Acad Sci 1998: 853: 270-272.
163. Asakura M, Kitakaze M, Takashima S, Sakata Y, Ogai A, Fukushima T et al. Myocardial ischemia largely changes cardiac gene expression detected by cDNA microarray technique in mice: role of endogenous adenosine. Circulation 1999: 100 (Suppl): A56.
164. Weinbrenner C, Liu G-S, Cohen MV, Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 1997: 29: 2383-2391.
165. Ogilby JD, Heo J, Iskindrian AS. Effect of adenosine on coronary blood flow and its use as a diagnostic test for coronary artery disease [Review]. Cardiovasc Res 1993: 27: 48-53.
166. Iskindrian AE, Heo J. Myocardial perfusion imaging during adenosine-induced coronary hyperemia. Am J Cardiol 1997: 79: 20-24.
167. Edlund A, Sollevi A, Linde B. Haemodynamic and metabolic effects of infused adenosine in man. Clin Sci 1990: 79: 131-138.
168. Meller ST, Gebhart GF. A critical review of the afferent pathways and the potential chemical mediators involved in cardiac pain. Neuroscience 1992: 48: 501-524.
169. Crea F, Gaspardione A, Kaski JC, Davies G, Maseri A. Relation between stimulation site of cardiac afferent nerves by adenosine and distribution of cardiac pain: results of a study in patients with stable angina. J Am Coll Cardiol 1992: 20: 1498-1502.
170. Gaspardone A, Crea F, Tomai F, Versaci F, Iamele M, Gioffre G et al. Muscular and cardiac adenosine-induced pain is mediated by A1 receptors. J Am Coll Cardiol 1995: 25: 251-257.
171. Stringham JC, Love RB, Welter D, Canver CC, Mentzer Jr RM. Impact of University of Wisconsin Solution on clinical heart transplantation. A comparison with Stanford Solution for extended preservation. Circulation 1998: 98 (Suppl II): II-157-II-162.
172. Fremes SE, Zhang J, Furukawa RD, Mickle DA, Weisel RD. Adenosine pretreatment for prolonged cardiac storage. An evaluation with St. Thomas' Hospital and University of Wisconsin solutions. J Thorac Cardiovasc Surg 1995: 110: 293-301.
173. Mentzer Jr RM, Rahko PS, Molina-Viamonte V, Canver CC, Chopra PS, Love RB et al. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol 1997: 79: 38-43.
174. Fremes SE, Levy SL, Christakis GT, Walker SE, Iazetta J, Feder-Elituv R et al. Phase 1 human trial of adenosine-potassium cardioplegia. Circulation 1996: 94 (Suppl II): II-370-II-375.
175. Cohen G, Feder-Elituv R, Iazetta J, Bunting P, Mallidi H, Bozinovski J et al. Phase 2 studies of adenosine cardioplegia. Circulation 1998: 98 (Suppl II): II-225-II-233.
176. Van der Starre PJA, Bakhuizen R, Nanninga J, de Kluiver EP, van Gool R, de Vries A. Cardioprotective effect of nucleoside-transport inhibition in patient undergoing coronary artery bypass grafting (CABG). Anesth Analg 994: 78: S453.
177. Andersen K, Dellborg M, Swedberg K. Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharmacol 1996: 51: 7-13.
178. Leung JM, Stanley 3rd T, Mathew J, Curling P, Barash P, Salmenpera M et al. An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesth Analg 1994: 78: 420-434.
179. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmakologische myokardprotektion wahrend perkutaner transluminaler koronarangioplastie (PTCA) durch dipyridamol intrakoronar: hamodynamische, kontraktile und ventrikeldynamische kosequenzen. Z Kardiol 1995: 84: 898-910.
180. De Hert SG, Rodriques IE, Haenen LR, Ten Broecke PW, Boeckxsaens CJ, Gillebert TC. Effects of lidoflazine on left ventricular function in patients. J Cardiothorac Vasc Anesth 1997: 11: 42-48.
181. Lee HT, LaFaro RJ, Reed GE. Pretreatment of human myocardium with adenosine during open heart surgery. J Card Surg 1995: 10: 665-676.
182. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997: 95: 2500-2507.
183. Belhomme D, Florens E, Peynet J, Bel A, Tibourtine O, Kitakaze M et al. Does adenosine preconditioning truly improve cardioprotection during coronary artery bypass operations? Circulation 1999: 100 (Suppl): A386.
184. Granger CB. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol 1997: 79: 44-48.
185. Garratt KN, Holmes DR Jr, Molina-Vimonte V, Reeder GS, Hodge DO, Bailey KR et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J 1998: 136: 196-204.
186. Marzilli M, Marraccini P, Gliozheni E, Orsini E, Picano E. Intracoronary adenosine as an adjunct to combined use of primary angioplasty in acute myocardial infarction: beneficial effects on angiographically assessed no-reflow. J Am Coll Cardiol 1996: 28 (Suppl): A406.
187. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999: 34: 1711-1720.
188. Kopecky SL, Midei GM, Kellett MA, Butler JF, Holland AE, Zannikos PN et al. Report of AMP579 delivery for myocardial infarction reduction (ADMIRE). Circulation 1999: 100 (Suppl): A651.
189. Van de Werf F, Janssens L, Brzostek T, De Geest H. Effects of increased myocardial adenosine concentrations in patients with acute myocardial infarction receiving thrombolytic therapy. Circulation 1992: 86 (Suppl): A803.
|
Language: | English.
|
Document Type: | Review Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0001-5172
|
NLM Journal Code: | 0370270
|
Annotation(s) | |
|
|